LEADER 10987nam 2200541 450 001 9910555163203321 005 20220712184908.0 010 $a1-119-61715-4 010 $a1-119-61714-6 010 $a1-119-61711-1 035 $a(CKB)4950000000280196 035 $a(MiAaPQ)EBC6787679 035 $a(Au-PeEL)EBL6787679 035 $a(OCoLC)1281959341 035 $a(EXLCZ)994950000000280196 100 $a20220712d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNeglected tropical diseases and phytochemicals in drug discovery /$fedited by Chukwuebuka Egbuna, Muhammad Akram, Jonathan Chinenye Ifemeje 210 1$aHoboken, New Jersey :$cJohn Wiley & Sons, Inc.,$d[2022] 210 4$dİ2022 215 $a1 online resource (624 pages) 311 $a1-119-61660-3 327 $aCover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Part I Introduction to Neglected Tropical Diseases -- Chapter 1 Epidemiology of Neglected Tropical Diseases -- List of Abbreviations -- 1.1 Introduction -- 1.2 Protozoan Infections -- 1.2.1 Human African Trypanosomiasis -- 1.2.2 Chagas Disease (American Trypanosomiasis) -- 1.2.3 Leishmaniasis -- 1.2.4 Amoebiasis -- 1.3 Helminth Infections -- 1.3.1 Soil-Transmitted Helminthiasis Infections -- 1.3.2 Schistosomiasis -- 1.3.3 Echinococcosis -- 1.3.4 Lymphatic Filariasis -- 1.3.5 Onchocerciasis ("River Blindness") -- 1.3.6 Foodborne Trematodiases -- 1.3.7 Dracunculiasis (Also Called Guinea Worm Disease) -- 1.4 Bacterial Infections -- 1.4.1 Yaws -- 1.4.2 Trachoma -- 1.4.3 Leprosy -- 1.4.4 Buruli Ulcer -- 1.5 Viral Infections -- 1.5.1 Rabies -- 1.5.2 Dengue -- 1.5.3 Chikungunya -- 1.6 Fungal and Ectoparasitic Infections -- 1.6.1 Chromoblastomycosis, Mycetoma/Eumycetoma, and Other Deep Mycoses -- 1.6.2 Scabies -- 1.6.3 Myiasis -- 1.7 Future Direction -- 1.8 Conclusion -- Acknowledgments -- References -- Chapter 2 Neglected Tropical Diseases, Phytochemicals, Protein Targets, and Mechanisms in Drug Discovery -- List of Abbreviations -- 2.1 Introduction -- 2.2 African Trypanosomiasis -- 2.2.1 Phytochemicals Against African Trypanosomiasis -- 2.3 Buruli Ulcer -- 2.3.1 Phytochemicals Against Buruli Ulcer -- 2.4 Chagas Disease -- 2.4.1 Phytochemicals Against Chagas Disease -- 2.5 Chikungunya -- 2.5.1 Phytochemicals Against Chikungunya -- 2.6 Dengue -- 2.6.1 Phytochemicals Against Dengue -- 2.7 Leishmaniasis -- 2.7.1 Phytochemicals Against Leishmaniasis -- 2.8 Leprosy -- 2.8.1 Indeterminate Leprosy -- 2.8.2 Phytochemicals Against Leprosy -- 2.9 Lymphatic Filariasis -- 2.9.1 Phytochemicals Against Lymphatic Filariasis -- 2.10 Mycetoma -- 2.10.1 Phytochemicals Against Mycetoma. 327 $a2.11 Onchocerciasis -- 2.11.1 Phytochemicals Against Onchocerciasis -- 2.12 Rabies -- 2.12.1 Phytochemicals Against Rabies -- 2.13 Scabies -- 2.13.1 Phytochemicals Against Scabies -- 2.14 Schistosomiasis -- 2.14.1 Phytochemicals Against Schistosomiasis -- 2.15 Conclusion -- References -- Chapter 3 Novel Bioactive Lead Compounds for Drug Discovery Against Neglected Tropical Diseases, Leishmaniasis, Lymphatic Filariasis, Trypanosomiasis (African Sleeping Sickness and Chagas Disease), and Schistosomiasis -- List of Abbreviations/Definitions -- 3.1 Introduction -- 3.2 Prevalence of Neglected Tropical Diseases -- 3.2.1 Leishmaniasis -- 3.2.2 Lymphatic Filariasis -- 3.2.3 Trypanosomiasis -- 3.2.3.1 African Trypanosomiasis (African Sleeping Sickness) -- 3.2.3.2 American Trypanosomiasis (Chagas Disease) -- 3.2.4 Schistosomiasis -- 3.3 Novel, Economical, and Efficacious Therapeutics from Medicinal Plants Against NTDs -- 3.3.1 Phytochemicals Effective Against Leishmania Parasite -- 3.3.2 Plants and Phytochemicals Effective Against Filarial Parasite -- 3.3.3 Plants and Phytochemicals Effective Against Trypanosomasis -- 3.3.4 Plants and Phytochemicals Effective Against Schistosomiasis -- 3.4 Future Prospects -- 3.5 Conclusion -- References -- Part II Protozoan Infections -- Chapter 4 Herbal, Nutritional, and Traditional Remedies for Giardiasis: Phytochemicals as Drug Candidates -- List of Abbreviations -- 4.1 Introduction -- 4.1.1 Epidemiology and Symptoms of Giardiasis -- 4.1.2 Life Cycle of G. duodenalis -- 4.1.3 Pathophysiology of Giardial Infection -- 4.1.4 Resistance to Allopathic Drug and Relevance of Herbal Medication -- 4.2 Plant-Based Dietary Supplements for Giardiasis Management -- 4.2.1 Oligosaccharide and Disaccharidase Supplementation -- 4.2.2 Dietary Fiber-Enriched Food -- 4.2.3 Agglutinin from Wheat -- 4.2.4 Vitamin and Mineral Supplements. 327 $a4.2.4.1 Vitamin A Supplementation -- 4.2.4.2 Compensation of Vitamin B12 -- 4.2.4.3 Zinc Status Management -- 4.2.5 Fermented Vegetables as Probiotic Source -- 4.2.6 Phenolic Compound Enriched Plant Food -- 4.3 Traditional Treatment of Giardiasis with Herbal Ethnomedicine -- 4.3.1 Hints of Antiprotozoal Medicines from Ancient Communities -- 4.3.2 Domestic Remedies and Alternative Medicine for Giardiasis -- 4.3.3 Applied Spectrum of Ethnopharmacology in Different Continents -- 4.3.3.1 Asian Medicinal Extracts -- 4.3.3.2 African Traditional Medicines -- 4.3.3.3 South American Ethnomedicine -- 4.4 Phytochemical Candidates for Advanced Giardicidal Drug Development -- 4.4.1 Terpenoids -- 4.4.2 Aromatic Ether -- 4.4.3 Alkaloids -- 4.4.4 Organo-sulfur Compounds -- 4.4.5 Lipids and Steroids -- 4.4.6 Phenolic Compounds -- 4.5 Future Prospects -- 4.5.1 Extension of Medicinal Compound Screening -- 4.5.2 Methodical Studies on Toxicology and Drug Adversity -- 4.5.3 Correlation of Herbal Drugs with Molecular Targets of Giardia -- 4.6 Summary, Prospects, and Conclusion -- References -- Chapter 5 Antiprotozoal Activity of Phytochemicals Against Entamoeba histolytica, the Causative Agent of Amoebiasis -- List of Abbreviations -- 5.1 Introduction -- 5.2 Life Cycle of Entamoeba histolytica -- 5.3 Diagnostic Techniques for Identification of E. histolytica -- 5.3.1 Intestinal Amoebiasis -- 5.3.1.1 Microscopy -- 5.3.1.2 Culture and Isoenzyme Analysis -- 5.3.1.3 Antigen Detection Test -- 5.3.1.4 Molecular-Based Test -- 5.3.1.5 Point-of-Care (POC) Test -- 5.4 Treatment of Amoebiasis -- 5.5 Alternative Treatment for Amoebiasis -- 5.6 Chemical Structure of Phytochemicals Effective Against E. histolytica -- 5.7 Possible Mechanisms of Phytochemicals as Antiamoebic -- 5.8 Future Projections -- 5.9 Conclusion -- References -- Chapter 6 Antileishmanial Potentials of Phytochemicals. 327 $a6.1 Introduction -- 6.2 Antileishmanial Activity of Propolis -- 6.2.1 Propolis from Turkey -- 6.2.2 Propolis from Brazil -- 6.2.3 Propolis from Portugal -- 6.2.4 Propolis from Cuba -- 6.2.5 Propolis from Ecuador -- 6.3 Antileishmanial Activity of Wild Mushrooms -- 6.4 Antileishmanial Activity of Medicinal Plants from Various Flora -- 6.4.1 Peruvian Flora -- 6.4.2 Ecuadorean Flora -- 6.4.3 Mexican Flora -- 6.4.4 Bolivian Flora -- 6.4.5 Iranian Flora -- 6.5 Antileishmanial Activity of Chemical Constituents -- 6.5.1 Alkaloids -- 6.5.2 Flavonoids -- 6.5.3 Terpenes -- 6.5.4 Glycoglycerolipids -- 6.5.5 Guttiferone A as a Lead Compound for Semisynthesis of Antileishmanial Molecules -- 6.6 Conclusion -- References -- Part III Helminth Infections -- Chapter 7 Prospects of Phytochemicals for the Treatment of Helminthiasis -- List of Abbreviations -- 7.1 Introduction -- 7.1.1 History -- 7.1.2 Prevalence -- 7.2 Molecular Characteristics of Soil-transmitted Helminthiasis -- 7.3 Clinical Features and Pathogenesis -- 7.4 Prevention -- 7.5 Treatment -- 7.6 Plants and Phytochemicals with Anthelmintic Activities -- 7.6.1 Modes of Action of Phytochemical Against the Soil-transmitted Helminthiasis -- 7.7 Scientific Reports of Medicinal Plants with Anthelmintic Properties -- 7.7.1 Adhatoda vasica -- 7.7.2 Allium sativum -- 7.7.3 Baliospermum montanum Muell -- 7.7.4 Butea monosperma -- 7.7.5 Calotropis procera -- 7.7.6 Carica papaya -- 7.7.7 Ficus benghalensis -- 7.7.8 Mimosa pudica -- 7.7.9 Punica granatum -- 7.7.10 Verbascum thapsus -- 7.7.11 Zingiber officinale -- 7.8 Future Prospects -- 7.9 Conclusion -- References -- Chapter 8 Efficacy of Phytochemicals of Medicinal Plants for the Treatment of Human Echinococcosis: Echinococcal Disease, Hydatidosis, or Hydatid Disease Drug Discovery -- List of Abbreviations -- 8.1 Introduction -- 8.2 Molecular Analysis. 327 $a8.3 Life Cycle of Echinococcosis -- 8.4 Previous Studies on the Positive Effects of Medicinal Plants and Phytochemicals -- 8.4.1 In vitro and in vivo Effect of Phytochemicals Against Echinococcus Infection -- 8.5 Synthetic Drugs Previously Used for Management of Echinococcosis Disease -- 8.6 Conclusion and Future Prospects -- References -- Chapter 9 Filaricidal Activity of Phytochemicals Against Lymphatic Filariasis -- List of Abbreviations -- 9.1 Introduction -- 9.2 Life Cycle of the Parasite -- 9.3 Synthetic Drugs Used for Treatment of Lymphatic Filariasis -- 9.4 Phytochemicals Used for the Treatment of Lymphatic Filariasis -- 9.4.1 Acacia auriculiformis -- 9.4.2 Aegle marmelos -- 9.4.3 Alnus nepalensis -- 9.4.4 Andrographis paniculata -- 9.4.5 Azadirachta indica -- 9.4.6 Bauhinia racemosa -- 9.4.7 Butea monosperma -- 9.4.8 Caesalpinia bonducella -- 9.4.9 Cardiospermum halicacabum -- 9.4.10 Centratherum anthelminticum -- 9.4.11 Excoecaria agallocha -- 9.4.12 Ficus racemosa -- 9.4.13 Glycyrrhiza glabra -- 9.4.14 Hibiscus sabdariffa -- 9.4.15 Lantana camara -- 9.4.16 Leucas cephalotes -- 9.4.17 Mallotus philippensis -- 9.4.18 Morinda citrifolia -- 9.4.19 Moringa oleifera -- 9.4.20 Plumbago indica -- 9.4.21 Pongamia pinnata -- 9.4.22 Psoralea corylifolia -- 9.4.23 Ricinus communis -- 9.4.24 Saxifraga stracheyion -- 9.4.25 Sphaeranthus indicus -- 9.4.26 Streblus asper -- 9.4.27 Trachyspermum ammi -- 9.4.28 Vitex negundo -- 9.4.29 Xylocarpus granatum -- 9.4.30 Zingiber officinale -- 9.5 Future Perspective -- 9.6 Conclusion -- References -- Chapter 10 Dracunculiasis (Guinea Worm Disease) and Phytochemicals in Drug Discovery -- List of Abbreviations -- 10.1 Introduction -- 10.2 Historical Insights of Dracunculiasis -- 10.3 Prevalence, Burden, and Distribution of Disease -- 10.4 Life Cycle, Pathogenesis, and Clinical Manifestations of Dracunculiasis. 327 $a10.5 Prevention and Eradication of Disease. 606 $aTropical medicine 606 $aPhytochemicals$xTherapeutic use 608 $aElectronic books. 615 0$aTropical medicine. 615 0$aPhytochemicals$xTherapeutic use. 676 $a616.9883 702 $aIfemeje$b Jonathan Chinenye 702 $aAkram$b Muhammad$f1980- 702 $aEgbuna$b Chukwuebuka 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910555163203321 996 $aNeglected tropical diseases and phytochemicals in drug discovery$92900716 997 $aUNINA LEADER 05320nam 2200757 450 001 9910812068303321 005 20240219161626.0 010 $a1-118-89933-4 010 $a1-118-89925-3 010 $a1-118-89935-0 024 7 $a10.1002/9781118899250 035 $a(CKB)3710000000224357 035 $a(EBL)1770415 035 $a(OCoLC)881387618 035 $a(SSID)ssj0001334913 035 $a(PQKBManifestationID)11729504 035 $a(PQKBTitleCode)TC0001334913 035 $a(PQKBWorkID)11289848 035 $a(PQKB)10252233 035 $a(CaBNVSL)mat08040077 035 $a(IDAMS)0b00006485f0e390 035 $a(IEEE)8040077 035 $a(DLC) 2014014209 035 $a(Au-PeEL)EBL1770415 035 $a(CaPaEBR)ebr10912887 035 $a(CaONFJC)MIL639086 035 $a(CaSebORM)9781118611661 035 $a(MiAaPQ)EBC1770415 035 $a(PPN)250964384 035 $a(EXLCZ)993710000000224357 100 $a20171024d2008 uy 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSmart data pricing /$f.edited by Soumya Sen, Carlee JoeWong, Sangtae Ha, and Mung Chiang 205 $a1st edition 210 1$aHoboken, New Jersey :$cWiley,$d2014. 210 2$a[Piscataqay, New Jersey] :$cIEEE Xplore,$d[2014] 215 $a1 online resource (1183 p.) 225 1 $aInformation and communication technology series 225 1 $aWiley series on information and communication technology 300 $aIncludes index. 311 $a1-118-61166-7 311 $a1-322-07835-1 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $a-- FOREWORD xv -- PREFACE xvi -- CONTRIBUTORS xx -- I SMART DATA PRICING IN TODAY'S ECOSYSTEM 1 -- 1 Will Smart Pricing Finally Take Off? 3 / Andrew Odlyzko -- 2 Customer Price Sensitivity to Broadband Service Speed: What Are the Implications for Public Policy? 35 / Victor Glass, Stela Stefanova, and Ron Dibelka -- 3 Network Neutrality with Content Caching and Its Effect on Access Pricing 47 / Fatih Kocak, George Kesidis, and Serge Fdida -- II TECHNOLOGIES FOR SMART DATA PRICING 67 -- 4 Pricing under Demand Flexibility and Predictability 69 / Ozgur Dalkilic, John Tadrous, Atilla Eryilmaz, and Hesham El-Gamal -- 5 Dual Pricing Algorithms by Wireless Network Duality for Utility Maximization 97 / Chee Wei Tan and Liang Zheng -- 6 Human Factors in Smart Data Pricing 127 / Soumya Sen, Carlee Joe-Wong, Sangtae Ha, and Mung Chiang -- III USAGE-BASED PRICING 167 -- 7 Quantifying the Costs of Customers for Usage-Based Pricing 169 / La?szlo? Gyarmati, Rade Stanojevic, Michael Sirivianos, and Nikolaos Laoutaris -- 8 Usage-Based Pricing Differentiation for Communication Networks: Incomplete Information and Limited Pricing Choices 195 / Shuqin Li and Jianwei Huang -- 9 Telecommunication Pricing: Smart Versus Dumb Pipes 241 / Atanu Lahiri -- IV CONTENT-BASED PRICING 267 -- 10 Economic Models of Sponsored Content inWireless Networks with Uncertain Demand 269 / Matthew Andrews, Ulas Ozen, Martin I. Reiman, and Qiong Wang -- 11 CDN Pricing and Investment Strategies under Competition 289 / Yang Song, Lixin Gao, and Arun Venkataramani -- 12 Smart Pricing and Market Formation in Hybrid Networks 321 / Aris M. Ouksel, Doug Lundquist, and Sid Bhattacharyya -- 13 To Tax or To Subsidize: The Economics of User-Generated Content Platforms 341 / Shaolei Ren and Mihaela van der Schaar -- V MANAGING CONTENT DELIVERY 363 -- 14 Spare Capacity Monetization by Opportunistic Content Scheduling 365 / Bell Labs and Alcatel-Lucent -- 15 Asynchronous Content Delivery and Pricing in Cellular Data Networks 391 / Vijay Gabale, Umamaheswari Devi, Ravi Kokku, and Shivkumar Kalyanraman. 327 $a16 Mechanisms for Quota Aware Video Adaptation 415 / Jiasi Chen, Amitabha Ghosh, and Mung Chiang -- 17 The Role of Multicast in Congestion Alleviation 441 / Alan D. Young -- VI PRICING IN THE CLOUD 453 -- 18 Smart Pricing of Cloud Resources 455 / Yu Xiang and Tian Lan -- 19 Allocating and Pricing Data Center Resources with Power-Aware Combinatorial Auctions 477 / Benjamin Lubin and David C. Parkes -- INDEX 501. 330 $a"As demand for data increases, Smart Data Pricing fills a market void in information on telecommunication economics. The book carefully addresses technical issues and workplace policies, system development and integration, research proposals, and business assessments. With both academic and industrial expertise from a variety of fields, Pricing is a practical and inclusive economics resource"--$cProvided by publisher. 330 $a"Provides insight on business strategies and initiatives through a diverse collection of perspectives"--$cProvided by publisher. 410 0$aWiley series on information and communication technology 606 $aTelecommunication$xPricing 606 $aResource allocation 615 0$aTelecommunication$xPricing. 615 0$aResource allocation. 676 $a384/.043 686 $aTEC061000$2bisacsh 701 $aSen$b Soumya$f1982-$01674481 801 0$bCaBNVSL 801 1$bCaBNVSL 801 2$bCaBNVSL 906 $aBOOK 912 $a9910812068303321 996 $aSmart data pricing$94039331 997 $aUNINA